Methods Of Treatment Of Pterygium Using An Anti-VEGF Agent
AssigneeCellviva, LLC
InventorRandal Tanh Hoang Pham
Life of this patent
Estimating the term…
Abstract
Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
Claims20
-11. (canceled)
A method of preventing pterygium recurrence in a patient in need thereof;
- wherein the patient has undergone pterygium removal in an eye at least once;
- comprising:
- a. treat the patient's eye with a topical anesthetic;
- and
- b. administer into the eye of the patient an anti-VEGF agent,
- wherein the administering of the anti-VEGF agent prevents pterygium recurrence for at least 1 month in the patient's eye post-surgical removal.
A method for treating pterygium recurrence comprising administering to an affected eye of a patient in need of such treatment, ranibizumab and an NSAID;
- wherein the administering prevents pterygium recurrence for at least 1 month in the patient's eye.
Dependencies are inferred from the claim text.